Education
About Us
Working with TipRanks
Follow Us
Bioventus (BVS)
NASDAQ:BVS
BVS Stock Chart & Stats
$8.77
-$0.12(-1.26%)
At close: 4:00 PM EST
$8.77
-$0.12(-1.26%)
Day’s Range― - ―
52-Week Range$5.81 - $11.25
Previous CloseN/A
Volume116.12K
Average Volume (3M)257.41K
Market Cap
$725.83M
Enterprise Value$866.13M
Total Cash (Recent Filing)$42.16M
Total Debt (Recent Filing)$322.58M
Price to Earnings (P/E)78.1
Beta0.91
Next Earnings
Mar 05, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding66,976,480
10 Day Avg. Volume219,442
30 Day Avg. Volume257,406
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)4.64
Price to Sales (P/S)1.20
P/FCF Ratio18.16
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue1.54
Enterprise Value/Gross Profit2.28
Enterprise Value/Ebitda9.66
Forecast
1Y Price Target
$14.00Price Target Upside59.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.77
Revenue Forecast (FY)$607.09M
Bulls Say, Bears Say
Bulls Say
Balance Sheet Leverage ReductionA dramatic reduction in debt-to-equity materially lowers financial risk and interest burden, improving flexibility for capital allocation. This stronger balance sheet supports continued R&D, commercialization investments, and opportunistic M&A without relying heavily on external financing.
Robust Free Cash Flow GenerationSustained FCF growth and high conversion of earnings into cash underpin durable internal funding for product launches, debt reduction, and working capital. Strong cash generation reduces reliance on capital markets and supports execution of strategic initiatives over the medium term.
New Product Approvals & Profitable Growth PotentialFDA-cleared product launches and a novel PRP system expand the addressable market in pain treatments and orthobiologics. New offerings that drive expected margin-accretive growth create a structural revenue and profitability tailwind if clinical adoption and reimbursement trends remain favorable.
Bears Say
Declining Revenue TrendA negative top-line trend erodes scale benefits and puts pressure on long-term operating leverage. Even with margin and cash improvements, sustained revenue declines complicate investment planning and make it harder to grow absolute EBITDA and fund strategic initiatives organically.
Modest Operating MarginsRelatively thin operating margins limit the company's capacity to absorb cost inflation, invest in commercialization, and translate gross profit strength into durable net returns. Continued margin expansion is required to convert gross margin advantages into sustainable shareholder value.
Revenue Impact From Divestiture And FXPortfolio pruning reduced recurring revenue base and makes growth comparisons lumpy; FX losses add volatility to reported results. These structural headwinds can hinder predictable top-line expansion and complicate medium-term guidance unless offset by strong organic adoption of new products.
Bioventus News
BVS FAQ
What was Bioventus’s price range in the past 12 months?
Bioventus lowest stock price was $5.81 and its highest was $11.25 in the past 12 months.
What is Bioventus’s market cap?
Bioventus’s market cap is $725.83M.
When is Bioventus’s upcoming earnings report date?
Bioventus’s upcoming earnings report date is Mar 05, 2026 which is tomorrow.
How were Bioventus’s earnings last quarter?
Bioventus released its earnings results on Nov 04, 2025. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.105 by $0.045.
Is Bioventus overvalued?
According to Wall Street analysts Bioventus’s price is currently Undervalued.
Does Bioventus pay dividends?
Bioventus does not currently pay dividends.
What is Bioventus’s EPS estimate?
Bioventus’s EPS estimate is 0.22.
How many shares outstanding does Bioventus have?
Bioventus has 66,976,480 shares outstanding.
What happened to Bioventus’s price movement after its last earnings report?
Bioventus reported an EPS of $0.15 in its last earnings report, beating expectations of $0.105. Following the earnings report the stock price went up 15.091%.
Which hedge fund is a major shareholder of Bioventus?
Currently, no hedge funds are holding shares in BVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioventus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (59.64% Upside)
$14.00 (59.64% Upside)
Hedge Fund Trend
Increased
By 11.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $75.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 13.8%
Last 30 Days ▲ 13.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.17%
12-Months-Change
Fundamentals
Return on Equity
4.97%
Trailing 12-Months
Asset Growth
-8.82%
Trailing 12-Months
Company Description
Bioventus
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
BVS Company Deck
BVS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant organic growth, profitability improvements, and strategic advancements in new markets, alongside effective cash and debt management. The main challenge was the impact of prior divestitures and foreign exchange losses.View all BVS earnings summariesBVS Stock 12 Month Forecast
Average Price Target
$14.00
▲(59.64% Upside)
Technical Analysis
Ownership Overview
31.92% Insiders
8.09% Mutual Funds
46.30% Other Institutional Investors
5.22% Public Companies and
Individual Investors